| | 501437-28-1 Basic information More.. |
| Product Name: | BI-D1870 | | Synonyms: | BI-D1870;2-[(3,5-difluoro-4-hydroxyphenyl)aMino]-5,7-diMethyl-8-(3-Methylbutyl)-5,6,7,8-tetrahydropteridin-6-one;6(5H)-Pteridinone, 2-[(3,5-difluoro-4-hydroxyphenyl)amino]-7,8-dihydro-5,7-dimethyl-8-(3-methylbutyl)-;2-[(3,5-DIFLUORO-4-HYDROXYPHENYL)AMINO]-7,8-DIHYDRO-5,7-DIMETHYL-8-(3-METHYLBUTYL)-6(5H)-PTERIDINONE;2-(3,5-Difluoro-4-hydroxyphenylamino)-5,7-dimethyl-8-(3-methylbutyl)-7,8-dihydro-5H-pteridin-6-one;CS-606;BID1870;BI-D 1870;BI-D1870 USP/EP/BP | | CAS: | 501437-28-1 | | MF: | C19H23F2N5O2 | | MW: | 391.42 | | EINECS: | | | Mol File: | 501437-28-1.mol |  |
Use
The 90 kDa ribosomal S6 kinases (RSKs) are a group of serine/threonine kinases involved in diverse cellular processes, including growth, survival, and motility. BI-D1870 is a cell permeable, ATP-competitive inhibitor of the four vertebrate isoforms of RSK, RSK1-4 (IC50s = 31, 24, 18, and 15 nM, respectively). At 100 nM, it also significantly inhibits polo-like kinase 1, Aurora B, maternal embryonic leucine zipper kinase, and mammalian STE20-like kinase 2. BI-D1870 acts at the N-terminal kinase domain, but not the C-terminal domain, of RSK.
|
|
501437-28-1
Recommend Suppliers |
|